samedan logo
 
 
 
spacer
home > ebr > spring 2003 > catching the code
PUBLICATIONS
European Biopharmaceutical Review

Catching the Code

The evolving fields of genomics and proteomics are developing into essential tools in the discovery and development of new medicines. A wide variety of techniques have been developed which allow the detection of information ranging from a single nucleotide polymorphism (SNP) to complete expression profiles. Despite these advances there remains an ongoing drive to reduce the cost of research and development in order to minimise the expense of bringing a new drug or diagnostic to market. As such, there is increasing demand for large-scale bioassay analysis using smaller reagent volumes and at a lower cost per test. As a result a variety of 'multiplexing' technologies have emerged over the last few years which allow researchers to perform millions of parallel biological tests on a miniature scale.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Ciaran Sewter and Dr Mark Evans, Development Scientists, and Dr Elizabeth Hill, Chief Executive Officer at 3D Molecular Sciences Ltd

Dr Ciaran Sewter is a Development Scientist at 3D Molecular Sciences Ltd. He has a BSc in Biological Sciences from the University of East Anglia and a PhD from the University of Cambridge.

Dr Sewter has expertise in molecular and cell biology and has held a number of academic and industrial positions in obesity/diabetes research, immunology and virology.

Dr Mark Evans works as a Development Scientist at 3D Molecular Sciences Ltd. Having completed his first degree in Biochemistry at the University of Plymouth, Dr Evans obtained a PhD from the Department of Analytical Chemistry at Loughborough University, based on the development of biospecific assays for drugs of pharmaceutical interest. After two years as a Research Fellow, he became Head of Assay Automation at Kalibrant Ltd, before joining 3D Molecular Sciences in October 2002. His main areas of expertise are fluidics, instrumentation, automation, solid state devices and fluorescence.

Dr Elizabeth Hill is Chief Executive Officer and Co-Founder of 3D Molecular Sciences Ltd. She has 20 years' experience in the biotechnology, life sciences and health care sectors. Dr Hill started her career in instrumentation with Philips Scientific, subsequently moving into biotechnology, where she was a principal participant in the MBO of Enzymatix leading to Chiroscience and Celsis, and the subsequent IPO of the latter. She graduated with a First Class Honours degree in Chemistry and was awarded a PhD at King's College London for developing electrochemiluminescence as a detection technique for HPLC.
spacer
Dr Elizabeth Hill
spacer
spacer
spacer
Dr Mark Evans
spacer
spacer
spacer
Dr Sewter
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Lynparza recommended for approval in EU by CHMP for BRCA-mutated metastatic pancreatic cancer

AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced that Lynparza (olaparib) has been recommended for marketing authorisation in the European Union (EU) for the 1st-line maintenance treatment of patients with germline BRCA-mutated (gBRCAm) metastatic pancreatic cancer. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the Phase III POLO trial, which were published in The New England Journal of Medicine.
More info >>

White Papers

Streamlining patient recruitment using EHR data

The field of (bio)pharmaceutical research is booming. Increasingly more innovative therapeutics are being developed with the ability to drastically improve the quality of life of millions of patients around the world. Rigorously testing each of these candidate drugs for their safety and efficacy is an essential part of the development process. As the number of clinical trials steadily increases, the search for patients who present a specific medical profile and are willing to participate intensifies.
More info >>

 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement